Impact and Applications
The technologies we have developed are suitable for a wide range of applications and we are certain they have a significant impact on cell culturing techniques
Cultured meat is known as an area of high growth potential as it requires far less land and water than conventional meat, will produce exponentially less climate change, and eliminates the severe environmental repercussions of animal waste and contamination via runoff. It also requires no antibiotics, produces no bacterial contamination, and will not harm animals.
However, despite its great promise, scaling up cellular meat production is a considerable and costly cell culture hurdle for these companies. A small steak will contain 10 billion adherent cells and using traditional batch processes could take a single bioreactor 1 month to produce, our biotechnology company could shorten that to a few days.
Our Impact for Cultured Meat
We can ensure that cultured meat companies can both eliminate serum from their production process and allow them to change from batch to continuous production. What this means is that it allows them to make truly ‘clean’ products, to increase their yield and to lower production costs.
This, in turn, allows them to create an impact for themselves by being able to successfully commercialize their products and create an actual market for cultured meat with its ethical, sustainability, health and other benefits.
Biologics are pharmaceuticals made from proteins and other substances produced by the body. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy.
Unlike conventional pharmaceuticals, Biologics are manufactured using living biological systems. Due to this, biopharmaceutical manufacturing requires specialized equipment and devices such as incubators that can support these biological systems. The cost of these devices and equipment is high as compared to regular manufacturing equipment. The majority of biologics products are manufactured using suspended cells. However, wherever adherent cells are used, there will be opportunities for sales of coatings by CellulaREvolution.
Cell therapies are generally working by injecting cell-based materials such as stem cells into the patients, with the goal of treating often rather severe diseases. The challenge for allogeneic cellular therapies is around donor matching, scaling up manufacture and quality assurance in the donation process to reduce the risk of transplant-related complications. Within a continuous bioreactor, cells can be harvested individually, rather than all together as a batch. This enables a radical change in quality assurance, as theoretically each cell produced could be analysed by flow cytometry and only cells that meet specific criteria subsequently used. As a result, the final population of cells for transplanting will have a much narrower, more precise, homogeneous character, whilst at the same time improving on scale.